Amol Akhade shared a post on LinkedIn:
“Doxorubicin plus Trabectedin followed by Trabectedin maintenance for leiomyosarcoma shows OS benifit vs doxorubicin alone .
Median OS Improved from 24 months to 33 months .
See the post progression therapy for both arms ( 36 % of control arm got Trabectedin on progression)
See the results of previous trials in same setting. ( gemcitabine plus docetaxel had median OS of 26.9 months).”
Source: Amol Akhade/LinkedIn
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.
